

DATE: February 19, 2004

SHEET 1 of 1

## Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE  
(Modified) PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
6690USC1SERIAL NO. 10782582  
(not yet assigned)INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

APPLICANT(S)

R. A. Craig, et al.

FILING DATE

February 19, 2004

GROUP

(not yet assigned)

(Use several sheets if necessary)

(37 CFR 1.98 (b))

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	INVENTOR	CLASS	SUB CLASS	FILING DATE
<i>826</i>	A1	5,977,408	11/2/1999	Levin, et al.	562	622	—

## FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

		DOCUMENT NUMBER	PUBLIC- ATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANS- LATION YES NO
<i>826</i>	B1	9831710	20.01.2000	DE	—	—	— —
	B2	266950	11.05.1988	EP	—	—	— —
	B3	99/57098	11.11.1999	WO	—	—	— —
<i>826</i>	B4	99/42436	26.08.1999	WO	—	—	— —

## OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

<i>826</i>	C1	Castro-Pichel, et al., "Synthesis & antiviral & cystatic activities," Nucleos. & Nucleot. 9(7):985-1000 (1990)
<i>826</i>	C2	Griffith, E.C., "Methionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin," Chemistry and Biology 4(6):461-471 (1997)
<i>826</i>	C3	Sin, Ny; "The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2," Proc. National Academy of Science USA 94:6099-6103 (1997)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO 1449)